Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. - de Botton, Stéphane; Brandwein, Joseph M.; Wei, Andrew H.; Pigneux, Arnaud; Quesnel, Bruno; Thomas, Xavier; Legrand, Ollivier; Recher, Christian; Chantepie, Sylvain; Hunault‐Berger, Mathilde; Boissel, Nicolas; Nehme, Salem A.; et al. (Cancer Medicine, 2021)